Engineering of crystalline combination inhalation particles of a long-acting beta2-agonist and a corticosteroid
Pitchayajittipong, C., Shur, J. and Price, R., 2009. Engineering of crystalline combination inhalation particles of a long-acting beta2-agonist and a corticosteroid. Pharmaceutical Research, 26 (12), pp. 2657-2666.
Related documents:This repository does not currently have the full-text of this item.
You may be able to access a copy if URLs are provided below. (Contact Author)
PURPOSE: Engineering of inhalation particles incorporating, in each individual particle, a combination of a long-acting beta-agonist and a glucocorticosteroid in a pre-determined and constant ratio for delivery via a dry powder inhaler (DPI). METHODS: Individual crystalline particles containing both the glucocorticosteroid fluticasone propionate (FP) and long-acting beta-agonist salmeterol (SX) were prepared, in a ratio of 10:1, using the solution atomization and crystallization by sonication (SAX) process. Combination drug particles were characterized by particle size, morphology, crystallinity and aerosolisation efficiency using inertial impaction. RESULTS: Combination drug particles were spherical and crystalline, with a median diameter of 4.68 +/- 0.01 microm. Aerosolisation of formulations containing combination drug particles resulted in greater uniformity in delivery ratios of both actives across all stages of the impactor before and after storage. CONCLUSIONS: Actives in a pre-determined dose ratio can be crystallised in a single particle using the SAX process.
|Creators||Pitchayajittipong, C., Shur, J. and Price, R.|
|Uncontrolled Keywords||administration, inhalation,adrenal cortex hormones,adrenergic beta-agonists,albuterol,androstadienes,bronchodilator agents,calorimetry, differential scanning,drug combinations,drug storage,inhalation,microscopy, electron, scanning,particle size,powders,protein engineering|
|Departments||Faculty of Science > Pharmacy & Pharmacology|
Actions (login required)